Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Labroots1d
Severe H5N1 Prevented in Monkeys with Antibody Therapy
The highly pathogenic avian influenza H5N1 infection has killed millions of birds around the world, and has spread to humans ...
News Medical2d
Pasteurization destroys influenza viruses in milk, reinforcing dairy safety
Pasteurization at 63°C and 72°C effectively inactivates influenza A viruses in milk, ensuring its safety for human ...
BioWorld5d
Updated RNA vaccine protects mice against emerging H5N1 strain
A recent study published in Nature Communications by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators evaluated a replicating RNA (repRNA) vaccine ...
poultrymed5d
mRNA vaccine protects chickens from divergent H5N1 viruses
The mRNA vaccine against avian influenza presents several advantages and disadvantages: Advantages: Rapid Development and Production; Non-Infectious Nature; Strong Immune Response; Adaptability to ...
AOL5d
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
But that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable. The Department of Health and Human ...